Daily Sepsis Research Analysis
Analyzed 12 papers and selected 3 impactful papers.
Summary
Immunometabolic signaling emerged as a key driver in sepsis pathophysiology, with intracellular lactic acidification shown to activate the NLRP3 inflammasome and even directly process pro-inflammatory cytokines. Clinically, adding anaerobic blood culture bottles improved pathogen recovery and altered therapy, while reduced LAMB2 levels correlated with organ dysfunction and 28-day mortality risk, supporting biomarker-guided risk stratification.
Research Themes
- Immunometabolism and inflammasome signaling in sepsis
- Biomarker discovery for severity and mortality risk stratification
- Diagnostic microbiology workflow optimization in suspected sepsis
Selected Articles
1. Lactic acid drives NLRP3 inflammasome activation and caspase-1-like cytokine cleavage via intracellular acidification.
This mechanistic study shows that intracellular lactic acidification is a potent signal for NLRP3 inflammasome activation and that lactic acid can directly cleave pro-IL-1β/IL-18 at caspase-1-like sites. In a murine cecal ligation and puncture sepsis model, systemic lactate exacerbated inflammation and worsened survival, linking hyperlactatemia to detrimental innate immune activation.
Impact: It uncovers a dual mechanism—metabolic acidification-driven inflammasome activation and inflammasome-independent cytokine processing—providing a unifying explanation for lactate-associated harm in sepsis.
Clinical Implications: Findings motivate evaluation of strategies that limit intracellular acidification (buffering, modulation of lactate production/efflux, or PKR/NLRP3 pathway inhibitors) and caution against iatrogenic lactate loading in severe sepsis until clinically validated.
Key Findings
- NLRP3 activators (nigericin/ATP) increased lactic acid production and intracellular acidification, promoting ASC speck formation, caspase-1 activation, and IL-1β release.
- Elevated extracellular lactate impaired lactate efflux, further acidifying the cytosol; extracellular alkalinization abolished inflammasome activation.
- Intracellular acidification induced mitochondrial dysfunction, ROS, and PKR phosphorylation, facilitating PKR–NLRP3 interaction and inflammasome assembly.
- Lactic acid directly cleaved pro-IL-1β at Asp116 and processed pro-IL-18; systemic lactate worsened inflammation and survival in CLP sepsis.
Methodological Strengths
- Multi-system validation (in vitro macrophages, biochemical assays, mass spectrometry, and in vivo CLP sepsis model).
- Mechanistic dissection linking acidification to mitochondrial dysfunction, ROS, and PKR–NLRP3 interactions.
Limitations
- Preclinical study without human validation; physiological relevance of lactate dosing requires careful calibration.
- No testing of targeted interventions (e.g., LDH inhibition or buffering) in survival-focused models.
Future Directions: Test pharmacologic or metabolic interventions that limit intracellular acidification or disrupt PKR–NLRP3 signaling in clinically relevant sepsis models and early-phase trials.
Glycolysis is critical for NLRP3 inflammasome activation, yet the link between lactic acid metabolism and inflammasome signaling remains unclear. Here, we show that stimulation of macrophages with the NLRP3 activators nigericin or ATP induces lactic acid production and efflux via a lactate dehydrogenase-dependent pathway. Accumulation of intracellular lactic acid leads to cytoplasmic acidification, which promotes NLRP3 inflammasome activation. Concurrently, elevated extracellular lactic acid impairs lactate efflux, exacerbating intracellular acidification and amplifying ASC speck formation, caspase-1 activation, and IL-1β secretion.
2. Diagnostic and Prognostic Value of LAMB2 in Sepsis Patients Admitted to the Intensive Care Unit.
In 172 ICU sepsis patients and 39 controls, lower LAMB2 levels—especially in septic shock—correlated with higher lactate, worse SOFA scores, and renal dysfunction. Serum LAMB2 predicted 28-day mortality with modest discrimination (AUC 0.676), supporting its role as an independent severity and mortality biomarker to complement existing scores.
Impact: Introduces LAMB2, a basement membrane component, as a clinically accessible biomarker linked to organ dysfunction and mortality risk in sepsis.
Clinical Implications: Serum LAMB2 could be integrated with lactate and SOFA for early risk stratification; given modest AUCs, it may be most useful as part of multi-marker panels pending external validation.
Key Findings
- Septic shock patients had significantly lower serum and monocyte LAMB2 than sepsis patients and healthy controls (p < 0.001).
- Serum LAMB2 strongly inversely correlated with lactate (r = -0.823); LAMB2 mRNA inversely correlated with SOFA (r = -0.361), creatinine (r = -0.426), and BUN (r = -0.304).
- Serum and mRNA LAMB2 predicted 28-day mortality (AUC 0.676 and 0.613, respectively), supporting prognostic utility.
Methodological Strengths
- Parallel assessment of serum protein and monocyte mRNA levels with standardized assays (ELISA, RT-qPCR).
- Use of multivariate modeling, ROC, and survival analysis with inclusion of healthy controls.
Limitations
- Single-center study with modest sample size and only 28-day outcomes; external validation is lacking.
- Diagnostic discrimination was modest; incremental value over established scores in diverse cohorts remains to be shown.
Future Directions: Prospective multicenter validation and exploration of mechanistic links between LAMB2 biology, endothelial/basement membrane integrity, and organ failure in sepsis.
OBJECTIVE: Sepsis is a major cause of mortality in intensive care unit (ICU) patients. The LAMB2 gene encodes laminin β2, a critical basement membrane component involved in maintaining tissue and organ integrity. However, the clinical significance of LAMB2 expression in sepsis diagnosis and prognosis remains unclear. This study aimed to evaluate the potential of LAMB2 as a biomarker for sepsis. METHODS: A total of 172 sepsis patients admitted to the ICU of the First Affiliated Hospital of Anhui Medical University between June 2023 and September 2024, and 39 non-septic healthy controls undergoing routine health examinations at the same hospital, were enrolled. All patients met the Sepsis 3.0 diagnostic criteria and were divided into sepsis (n=88) and septic shock (n=84) groups. Serum and monocyte LAMB2 levels were measured using ELISA and RT-qPCR, respectively. We also queried The Human Protein Atlas (HPA) datasets to profile baseline LAMB2 expression across human immune cell subsets. The diagnostic and prognostic value of LAMB2 was assessed via multivariate regression, ROC curve, and Kaplan-Meier survival analysis.
3. Real-Life Evaluation of Supplemental Anaerobic Blood Culture Bottles in the Virtuo System: Impact on Diagnosis and Therapeutic Management of Patients with Suspected Sepsis.
Among 498 pathogenic isolates, 16.7% were recovered only in anaerobic bottles and 56.4% in both; time to positivity did not differ from aerobic bottles. In cases with exclusive anaerobic recovery, 50.5% had documented antimicrobial therapy changes, supporting routine inclusion of anaerobic bottles in suspected sepsis workflows.
Impact: Demonstrates real-world diagnostic and therapeutic impact of adding anaerobic bottles, recovering otherwise-missed facultative anaerobes and prompting treatment modifications.
Clinical Implications: Adopting routine anaerobic bottles with aerobic sets can increase pathogen yield without delaying positivity, facilitating earlier and more appropriate antimicrobial selection.
Key Findings
- Of 498 pathogens, 16.7% were isolated exclusively in anaerobic bottles and 26.9% exclusively in aerobic bottles; 56.4% were in both.
- No significant difference in time to positivity between anaerobic and aerobic bottles (p > 0.05).
- In 50.5% of patients with exclusive anaerobic isolates, antimicrobial therapy was modified based on results.
Methodological Strengths
- Real-world cross-sectional design with standardized automated detection (BACT/Alert VIRTUO) and organism identification (MALDI-TOF VITEK MS).
- Paired aerobic–anaerobic sets per patient enabling within-case comparison.
Limitations
- Inclusion limited to episodes with at least one positive bottle, introducing selection bias; non-randomized design.
- Clinical outcomes beyond therapy changes (e.g., mortality, time to appropriate therapy) were not evaluated.
Future Directions: Prospective evaluation of patient-centered outcomes and cost-effectiveness of routine anaerobic bottle inclusion across diverse care settings.
OBJECTIVE: To evaluate the impact of the systematic inclusion of anaerobic blood culture bottles, in conjunction with aerobic bottles, in the diagnosis and management of patients with suspected sepsis, analyzing their effect on pathogen detection, time to positivity, and subsequent therapeutic modifications. METHODS: A cross-sectional observational study was conducted involving 565 patients weighing 36 kg or more with suspected bacteremia or fungemia. Two sets of blood culture bottles were collected per patient (each set consisting of one aerobic and one anaerobic bottle), with at least one bottle flagged as positive by the detection system. Samples were processed using the BACT/Alert VIRTUO automated system, and microorganisms were identified via MALDI-TOF VITEK MS mass spectrometry. Isolates and time to positivity were compared between both bottle types.